Gastrointestinal symptoms of Henoch-Schönlein purpura treated with mycophenolate mofetil.
Department of Pediatrics, Marshfield Clinic, WI 54449, USA.Journal of Pediatric Gastroenterology and Nutrition (impact factor: 2.3). 09/2006; 43(2):245-7. DOI:10.1097/01.mpg.0000189369.45158.e3 pp.245-7
Article: Henoch-Schönlein purpura.Archives of Disease in Childhood 05/1999; 80(4):380-3. · 2.88 Impact Factor
[show abstract] [hide abstract]
ABSTRACT: Henoch-Schönlein purpura (HSP) is the most common vasculitis of childhood. In this review, the main clinical features and complications are described. Although most features are self-limiting, renal disease is the most likely to result in long-term morbidity. Treatment of HSP nephritis is controversial, and the evidence for both prevention and treatment of established disease is reviewed. Follow-up for children presenting with HSP should be for at least 6 months and should include regular urine testing for proteinuria and haematuria and a blood pressure measurement. Women with a history of HSP during childhood are at increased risk of complications (such as proteinuria and hypertension) during pregnancy and should be monitored closely. This paper describes current practice with regard to investigation and management and proposes a practical care pathway of the management of a child with HSP.European Journal of Pediatrics 12/2009; 169(6):643-50. · 1.88 Impact Factor
Article: Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report.[show abstract] [hide abstract]
ABSTRACT: Background. Henoch-Schönlein purpura (HSP) is the most common childhood vasculitis with an incidence of approximately 10 per 100 000 children. There is some evidence to support steroid therapy in the treatment of severe abdominal pain, severe nephritis, and central nervous system involvement. However, the routine use of corticosteroids is controversial. Frequent relapses, lack of response to steroid, steroid dependency, and steroid side effects may occur in some patients. Mycophenolate mofetil (MMF) gains increasing popularity in the treatment of autoimmune disorders, but hitherto, the available evidence to support the use of MMF in HSP is limited to some case study reports. Case Presentation. We report six children with HSP who failed to respond to systemic steroid therapy, whereas MMF successfully treated the manifestations of the disease. Conclusion. The manifestations of HSP disappeared mainly during the first week of treatment with MMF and all the patients were in a complete remission at the end and after discontinuation of the therapy. In our experience, MMF appeared to be safe and effective for the maintenance of remission in the HSP patients.International Journal of Rheumatology 01/2010; 2010:254316.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.